石药集团(01093.HK) 公布，由集团开发的一类新药双功能融合蛋白药物JMT108，已获国家药品监督管理局批准，可在中国开展临床试验。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，本次获批的临床适应症为晚期恶性肿瘤。集团表示，临床前研究显示该产品的适应症广泛，在多种恶性肿瘤模型中具有显著的抗肿瘤作用及良好的安全性，具有较高的临床开发价值。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.